Identification | Back Directory | [Name]
EBI-2511 | [CAS]
2098546-05-3 | [Synonyms]
EBI-2511 EBI-2511;EBI2511;EBI 2511; Histone Methyltransferase,Inhibitor,EBI-2511,inhibit,EBI 2511,EBI2511 N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-ethyl-6-[ethyl(oxan-4-yl)amino]-2-(1-propan-2-ylpiperidin-4-yl)-1-benzofuran-4-carboxamide 4-Benzofurancarboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-ethyl-6-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-2-[1-(1-methylethyl)-4-piperidinyl]- | [Molecular Formula]
C34H48N4O4 | [MDL Number]
MFCD31715425 | [MOL File]
2098546-05-3.mol | [Molecular Weight]
576.77 |
Hazard Information | Back Directory | [Uses]
EBI-2511 is a highly potent and orally active EZH2 inhibitor, with an IC50 of 6 nM in Pfeffiera cell lines, respectively. | [in vivo]
EBI-2511 displays a dose-dependent inhibition on the tumor growth, resulting in 28% (10mg/kg), 83% (30mg/kg), and 97% (100mg/kg) reduction in tumor size. At the same dosage level, EBI-2511 shows a superior anti-tumor efficacy to EPZ-6438 (P<0.01). It is noteworthy that no significant changes in body weights of all treatment groups are observed[1]. | [IC 50]
EZH2 | [References]
[1] Lu B, et al. Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma. ACS Med Chem Lett. 2018 Jan 29;9(2):98-102. DOI:10.1021/acsmedchemlett.7b00437 |
|
Company Name: |
BOC Sciences
|
Tel: |
16314854226 |
Website: |
www.bocsci.com |
Company Name: |
DC Chemicals
|
Tel: |
021-58447131 13564518121 |
Website: |
http://m.is0513.com/ShowSupplierProductsList927327/0.htm |
Company Name: |
Energy Chemical
|
Tel: |
021-58432009 400-005-6266 |
Website: |
http://www.energy-chemical.com |
|